Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Armstrong

Showing results (1031-1040 of 1,067) with videos related to

Pageof 107
Sort By:
Bioorganic & Medicinal Chemistry Letters|August 18, 1999
Potent immunosuppressive C32-O-arylethyl ether derivatives of ascomycin with reduced toxicityH M Armstrong, F Wong, M A Holmes, et al.
Cardiovascular Research|September 4, 2015
A novel assay uncovers an unexpected role for SR-BI in LDL transcytosisSusan M Armstrong, Michael G Sugiyama, Karen Y Y Fung, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|April 18, 2018
Patterns of usage and preferences of users for tuberculosis-related text messages and voice calls in UgandaJ M Ggita, C Ojok, A J Meyer, et al.
The Prostate|July 12, 2019
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapyJinge Zhao, Mengni Zhang, Jiandong Liu, et al.
Histopathology|January 5, 2026
Analysis of SCLC subtype markers (ASCL1, NEUROD1, POU2F3, YAP1), DLL3, OTP, and TTF1 in 300 lung carcinoids and enteropancreatic neuroendocrine tumoursJonathan Willner, Irfan Khan, Zeynep Tarcan, et al.
Neobiota : Advancing Research on Alien Species and Biological Invasions|July 6, 2023
Population genetics of an invasive mosquito vector, <i>Aedes albopictus</i> in the Northeastern USAAndrea Gloria-Soria, Talya Shragai, Alexander T Ciota, et al.
Journal of Inherited Metabolic Disease|April 28, 2026
Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5 Years of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final ResultsMelissa P Wasserstein, Carla E Hollak, Antonio Barbato, et al.
JAMA Oncology|November 2, 2018
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical TrialLillian L Siu, Caroline Even, Ricard Mesía, et al.
Orphanet Journal of Rare Diseases|December 2, 2023
Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trialMelissa P Wasserstein, Robin Lachmann, Carla Hollak, et al.
Journal of General Internal Medicine|January 22, 2024
Improving Veteran Engagement with Virtual Care Technologies: a Veterans Health Administration State of the Art Conference Research AgendaTaona P Haderlein, Jenice Guzman-Clark, Navid S Dardashti, et al.
Pageof 107

Showing results (1031-1040 of 1,067) with videos related to

Sort By:
Pageof 107
Bioorganic & Medicinal Chemistry Letters|August 18, 1999
Potent immunosuppressive C32-O-arylethyl ether derivatives of ascomycin with reduced toxicityH M Armstrong, F Wong, M A Holmes, et al.
Cardiovascular Research|September 4, 2015
A novel assay uncovers an unexpected role for SR-BI in LDL transcytosisSusan M Armstrong, Michael G Sugiyama, Karen Y Y Fung, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|April 18, 2018
Patterns of usage and preferences of users for tuberculosis-related text messages and voice calls in UgandaJ M Ggita, C Ojok, A J Meyer, et al.
The Prostate|July 12, 2019
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapyJinge Zhao, Mengni Zhang, Jiandong Liu, et al.
Histopathology|January 5, 2026
Analysis of SCLC subtype markers (ASCL1, NEUROD1, POU2F3, YAP1), DLL3, OTP, and TTF1 in 300 lung carcinoids and enteropancreatic neuroendocrine tumoursJonathan Willner, Irfan Khan, Zeynep Tarcan, et al.
Neobiota : Advancing Research on Alien Species and Biological Invasions|July 6, 2023
Population genetics of an invasive mosquito vector, <i>Aedes albopictus</i> in the Northeastern USAAndrea Gloria-Soria, Talya Shragai, Alexander T Ciota, et al.
Journal of Inherited Metabolic Disease|April 28, 2026
Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5 Years of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final ResultsMelissa P Wasserstein, Carla E Hollak, Antonio Barbato, et al.
JAMA Oncology|November 2, 2018
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical TrialLillian L Siu, Caroline Even, Ricard Mesía, et al.
Orphanet Journal of Rare Diseases|December 2, 2023
Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trialMelissa P Wasserstein, Robin Lachmann, Carla Hollak, et al.
Journal of General Internal Medicine|January 22, 2024
Improving Veteran Engagement with Virtual Care Technologies: a Veterans Health Administration State of the Art Conference Research AgendaTaona P Haderlein, Jenice Guzman-Clark, Navid S Dardashti, et al.
Pageof 107